ReviewMolecular metabolism2021
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases.
Review in Molecular metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.Molecular metabolism · 2025Trial
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Review
- Brain Amylin Signaling, Feeding, and Reward.Comprehensive Physiology · 2026Review
- Epigenetics in migraine: the Junior Editorial Board Members' vision.The journal of headache and pain · 2025Review
- Amylin receptor subunit interactions are modulated by agonists and determine signaling.Science signaling · 2025Article
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.Nature communications · 2025Article
- Ventral tegmental area amylin / calcitonin receptor signaling suppresses feeding and weight gain in female rats.Neuroscience research · 2025Article
- Structural Analysis of Amylin and Amyloid β Peptide Signaling in Alzheimer's Disease.Biomolecules · 2025Article
- Evolving Approaches for Pharmacological Therapy of Obesity.Annual review of pharmacology and toxicology · 2025Review
- Photochemically-enabled, post-translational production of C-terminal amides.Nature communications · 2024Article
- NN1213 - A Potent, Long-Acting, and Selective Analog of Human Amylin.Journal of medicinal chemistry · 2024Article
- The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection - a novel disease-modifying osteoarthritis drug.Arthritis research & therapy · 2024Article
- New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.Biomedicines · 2024Review
- Cryo-EM Structure of the Human Amylin 1 Receptor in Complex with CGRP and Gs Protein.Biochemistry · 2024Article
- Influence of metabolic state and body composition on the action of pharmacological treatment of migraine.The journal of headache and pain · 2024Review
- Spinal afferent neurons: emerging regulators of energy balance and metabolism.Frontiers in molecular neuroscience · 2024Review
- The Insulin Sensitizer KBP-336 Prevents Diabetes-Induced Cognitive decline in ZDF Rats.The journal of prevention of Alzheimer's disease · 2024Article
- Future targets for migraine treatment beyond CGRP.The journal of headache and pain · 2023Review
- Identification of key immune genes of osteoporosis based on bioinformatics and machine learning.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and increase weight loss efficacy in combination with current treatment options. Calcitonin gene-related peptide (CGRP) and amylin belong to the same peptide family and have been explored as treatments for metabolic diseases. However, their full potential remains controversial. SCOPE OF REVIEW: In this article, we introduce this rather complex peptide family and its corresponding receptors. We discuss the physiology of the peptides with a focus on metabolism and insulin sensitivity. We also thoroughly review the pharmacological potential of amylin, calcitonin, CGRP, and peptide derivatives as treatments for metabolic diseases, emphasizing their ability to increase insulin sensitivity based on preclinical and clinical studies. MAJOR
conclusionsAmylin receptor agonists and dual amylin and calcitonin receptor agonists are relevant treatment candidates, especially because they increase insulin sensitivity while also assisting weight loss, and their unique mode of action complements incretin-based therapies. However, CGRP and its derivatives seem to have only modest if any metabolic effects and are no longer of interest as therapies for metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.